United Therapeutics Bilan de santé
Santé financière contrôle des critères 6/6
United Therapeutics possède un total de capitaux propres de $6.1B et une dette totale de $400.0M, ce qui porte son ratio d'endettement à 6.6%. Son actif total et son passif total sont $7.1B et de $1.0B. L'EBIT de United Therapeutics est $1.3B ce qui fait que son ratio de couverture des intérêts -8.9. Elle dispose de liquidités et de placements à court terme de $3.3B.
Informations clés
6.6%
Ratio d'endettement
US$400.00m
Dette
| Ratio de couverture des intérêts | -8.9x |
| Argent liquide | US$3.33b |
| Fonds propres | US$6.10b |
| Total du passif | US$1.02b |
| Total des actifs | US$7.12b |
Mises à jour récentes de la santé financière
Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 18
United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Jul 04Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?
Mar 15United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
Dec 08United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Sep 04United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
May 22Recent updates
United Therapeutics: One To Believe In Despite Competitive Threats
Nov 14Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 18Benign Growth For United Therapeutics Corporation (NASDAQ:UTHR) Underpins Its Share Price
Sep 27United Therapeutics: Economics Support Compounding Ability
Aug 20With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jul 26United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Jul 04United Therapeutics Corporation's (NASDAQ:UTHR) Business And Shares Still Trailing The Market
Jun 13United Therapeutics: Exciting Company With A Big Problem
Jun 02We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease
Apr 05United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects
Mar 20Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?
Mar 15Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings
Jan 02United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
Dec 08Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Nov 16United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Sep 04Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Aug 07United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
May 22Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?
Apr 25We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease
Feb 06With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jan 16Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 20United Therapeutics: Ability To Expand Tyvaso To Large IPF Market
Aug 24Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?
Aug 04Analyse de la situation financière
Passif à court terme: Les actifs à court terme de UTHR ( $4.0B ) dépassent ses passifs à court terme ( $873.4M ).
Passif à long terme: Les actifs à court terme de UTHR ( $4.0B ) dépassent ses passifs à long terme ( $148.8M ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: UTHR dispose de plus de liquidités que de sa dette totale.
Réduire la dette: Le ratio d'endettement de UTHR a été réduit de 36.8% à 6.6% au cours des 5 dernières années.
Couverture de la dette: La dette de UTHR est bien couverte par le flux de trésorerie opérationnel ( 284.2% ).
Couverture des intérêts: UTHR gagne plus d'intérêts qu'il n'en paie, donc la couverture des paiements d'intérêts n'est pas un problème.